Article Information
History
- February 22, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Emi Sano1,
- Ayaka Sakamoto1,
- Natsumi Mimura1,
- Ai Hirabayashi2,3,
- Yukiko Muramoto2,3,
- Takeshi Noda2,3,
- Takuya Yamamoto1,4,5,6 and
- Kazuo Takayama1,*
- 1Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan
- 2Laboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan
- 3CREST, Japan Science and Technology Agency (JST), Kawaguchi 332-0012, Japan
- 4Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto 606-8501 Japan
- 5Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto 606-8507, Japan
- 6AMED-CREST, Japan Agency for Medical Research and Development (AMED), Tokyo 100-0004, Japan
- ↵*Corresponding author Dr. Kazuo Takayama, Center for iPS Cell Research and Application, Kyoto University, Shogoin Kawaharacho 53, Sakyo-ku, Kyoto 606-8397, Japan, Phone: +81-75-366-7362, FAX: +81-75-366-7074, E-mail: kazuo.takayama{at}cira.kyoto-u.ac.jp
Posted February 22, 2021.
Modeling SARS-CoV-2 infection and its individual differences with ACE2-expressing human iPS cells
